Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Clinical trial NCT01294579 · COMPLETED
Trial details
- NCT number
- NCT01294579
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-05-17
- Primary completion
- 2016-12-20
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.